BioMAS — raw details

Highlights

1 patent

About

Tellurium based Drugs for Autoimmune Diseases

BioMAS Ltd is a clinical-stage company focusing on the invention, development, and commercialization of tellurium-based compounds. The companys lead molecules, AS101 and SAS, are small tellurium-based compounds developed for the treatment of various conditions. The molecules have integrin-inhibitory properties. Integrins are emerging therapeutic targets in many human pathologies. The companys AS101/SAS drugs have demonstrated preclinical and clinical safety and efficacy for autoimmune-inflammatory diseases (psoriasis, arthritis, Crohns, and MS), certain viral conditions (HPV warts), angiogenesis-related diseases (AMD), thrombocytopenia, neutropenia, and fertility preservation following chemotherapy and radiotherapy. A 15.4% stake in the company was acquired by Cosmo Pharmaceuticals (XSWS:COPN) for ILS 7 million on March 27, 2014.

Identity

Name	BioMAS
Slug	biomas
Type / kind	startup
Crunchbase ID	biomas
Source _id	agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7q_ekLDA

Status

Status	inactive
Status reason	Non Active, Mar 2014
Last update	2026-05-17

Location

HQ country code	IL
HQ region/district	Jerusalem District
HQ city	Jerusalem
HQ address	Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram

Classifications

Primary sector Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development

Technologies

Biologicals

Target customers

Healthcare & Life SciencesLife SciencesPharmaceuticals

Business models

B2B

Funding

Total raised	$2.0M
Current stage	Series A

Raw source document

Show full JSON (0 KB)

{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}